FDA Biotech Products Office Acting Director Is CBER Veteran Webber
Executive Summary
FDA Office of Biotechnology Products Acting Director Keith Webber, PhD, will bring a CBER perspective to the office's quality review functions
You may also be interested in...
CDER Office Of Biotech Products To Oversee Biologics Quality After Transition
Center for Drug Evaluation & Research Office of New Drug Chemistry Director Yuan-yuan Chiu, PhD, will serve as acting director of FDA's Office of Biotech Products when the office is officially established in October
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials